Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event.

Weschle L, Potratz J, Rutsch F, Humberg A, Oesingmann S, Pascher A, Busch AS, Masjosthusmann K

Endocrinology, diabetes & metabolism case reports29 Apr 2025

PMID40300042PMCIDPMC12063474DOI10.1530/edm-25-0006PepBankPUB-40300042

Summary

SummaryClinical management of congenital hyperinsulinism (CHI) remains a significant challenge due to its complex pathophysiology and the limitations of available therapies. Dasiglucagon, a synthetic glucagon analog, represents a novel approach to managing CHI, particularly in patients where conventional therapies fail. This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI. Despite initial stabilization of glycemic levels, the patient developed necrolytic migratory erythema (NME), a rare dermatological condition associated with hyperglucagonemia, during dasiglucagon therapy. The patient further experienced severe malnutrition, zinc and amino acid deficiencies, and sepsis. Following the discontinuation of dasiglucagon therapy due to these severe side effects, the patient's skin and nutritional status improved markedly. However, glycemic control required subtotal pancreatectomy. This report underscores the potential of dasiglucagon in CHI management but highlights the importance of close monitoring during prolonged therapy.Learning pointsNME, a rare but severe condition, appears to be associated with prolonged continuous subcutaneous dasiglucagon therapy, requiring early recognition and intervention. Close monitoring is essential during prolonged continuous subcutaneous dasiglucagon therapy to detect potential adverse effects, focusing on dermatological conditions, nutrient deficiencies or signs of infection. Multidisciplinary care is crucial to manage CHI with dasiglucagon, ensuring a comprehensive approach that addresses both glycemic control and potential side effects.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanCase report or seriesEfficacy outcome
In a neonate with congenital hyperinsulinism, dasiglucagon initially stabilized glycemic levels.
In plain wordsIn a neonate with congenital hyperinsulinism, dasiglucagon initially stabilized blood sugar.
Peptide
Dasiglucagon
Outcome
Not applicableInitial glycemic stabilization
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
Despite initial stabilization of glycemic levels, the patient developed necrolytic migratory erythema (NME), a rare dermatological condition associated with hyperglucagonemia, during dasiglucagon therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004201
02HumanCase report or seriesSafety outcome
A neonate developed necrolytic migratory erythema during prolonged dasiglucagon therapy.
In plain wordsA neonate developed necrolytic migratory erythema during prolonged dasiglucagon therapy.
Peptide
Dasiglucagon
Outcome
Not applicableNecrolytic migratory erythema
Study
n = 1
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
Despite initial stabilization of glycemic levels, the patient developed necrolytic migratory erythema (NME), a rare dermatological condition associated with hyperglucagonemia, during dasiglucagon therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004202
03HumanCase report or seriesSafety outcome
A neonate experienced severe malnutrition during dasiglucagon therapy.
In plain wordsA neonate experienced severe malnutrition during dasiglucagon therapy.
Peptide
Dasiglucagon
Outcome
Not applicableSevere malnutrition
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
The patient further experienced severe malnutrition, zinc and amino acid deficiencies, and sepsis.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004203
04HumanCase report or seriesSafety outcome
A neonate experienced zinc deficiency during dasiglucagon therapy.
In plain wordsA neonate experienced zinc deficiency during dasiglucagon therapy.
Peptide
Dasiglucagon
Outcome
Not applicableZinc deficiency
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
The patient further experienced severe malnutrition, zinc and amino acid deficiencies, and sepsis.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004204
05HumanCase report or seriesSafety outcome
A neonate experienced amino acid deficiencies during dasiglucagon therapy.
In plain wordsA neonate experienced amino acid deficiencies during dasiglucagon therapy.
Peptide
Dasiglucagon
Outcome
Not applicableAmino acid deficiencies
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
The patient further experienced severe malnutrition, zinc and amino acid deficiencies, and sepsis.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004205
06HumanCase report or seriesSafety outcome
A neonate experienced sepsis during dasiglucagon therapy.
In plain wordsA neonate experienced sepsis during dasiglucagon therapy.
Peptide
Dasiglucagon
Outcome
Not applicableSepsis
Study
n = 1
Outcome group
Adverse events · Infection
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
The patient further experienced severe malnutrition, zinc and amino acid deficiencies, and sepsis.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004206
07HumanCase report or seriesSafety outcome
Dasiglucagon was discontinued in a neonate because of severe side effects.
In plain wordsDasiglucagon was stopped in a neonate because of severe side effects.
Peptide
Dasiglucagon
Outcome
Not applicableTreatment discontinuation
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
Following the discontinuation of dasiglucagon therapy due to these severe side effects, the patient's skin and nutritional status improved markedly.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004207
08HumanCase report or seriesSafety outcome
The neonate's skin status improved markedly after dasiglucagon discontinuation.
In plain wordsThe neonate's skin improved markedly after dasiglucagon was stopped.
Peptide
Dasiglucagon
Outcome
Not applicableSkin status after discontinuation
Study
n = 1
Outcome group
Adverse events · Skin and wound
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
Following the discontinuation of dasiglucagon therapy due to these severe side effects, the patient's skin and nutritional status improved markedly.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004208
09HumanCase report or seriesSafety outcome
The neonate's nutritional status improved markedly after dasiglucagon discontinuation.
In plain wordsThe neonate's nutritional status improved markedly after dasiglucagon was stopped.
Peptide
Dasiglucagon
Outcome
Not applicableNutritional status after discontinuation
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
Following the discontinuation of dasiglucagon therapy due to these severe side effects, the patient's skin and nutritional status improved markedly.
1 context sentence(design, population, supporting numbers)
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004209
10HumanCase report or seriesEfficacy outcome
After dasiglucagon discontinuation, the neonate required subtotal pancreatectomy for glycemic control.
In plain wordsAfter dasiglucagon was stopped, the neonate needed subtotal pancreatectomy to control blood sugar.
Peptide
Dasiglucagon
Outcome
Not applicableSubsequent glycemic control
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · continuous subcutaneous infusionAs given in this study (human).
Source sentences
Summary
However, glycemic control required subtotal pancreatectomy.
2 context sentences(design, population, supporting numbers)
Summary · context
Following the discontinuation of dasiglucagon therapy due to these severe side effects, the patient's skin and nutritional status improved markedly.
Summary · context
This report discusses a rare case of prolonged continuous subcutaneous dasiglucagon use in a neonate with CHI.
Show in the study text Report a problemFND-4030004210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.